Organovo Holdings, Inc. (ONVO)

NASDAQ: ONVO · IEX Real-Time Price · USD
0.986
-0.024 (-2.38%)
At close: Feb 26, 2024, 3:57 PM
0.990
+0.004 (0.42%)
After-hours: Feb 26, 2024, 7:54 PM EST
-2.38%
Market Cap 10.04M
Revenue (ttm) 242,000
Net Income (ttm) -19.09M
Shares Out 10.04M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 57,403
Open 1.020
Previous Close 1.010
Day's Range 0.980 - 1.020
52-Week Range 0.890 - 2.720
Beta 0.91
Analysts n/a
Price Target n/a
Earnings Date Feb 8, 2024

About ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 18
Stock Exchange NASDAQ
Ticker Symbol ONVO
Full Company Profile

Financial Performance

In 2022, ONVO's revenue was $370,000, a decrease of -75.33% compared to the previous year's $1.50 million. Losses were -$17.26 million, 50.8% more than in 2021.

Financial Statements

News

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ...

4 weeks ago - GlobeNewsWire

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), in...

6 weeks ago - GlobeNewsWire

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory ...

2 months ago - GlobeNewsWire

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows:

3 months ago - GlobeNewsWire

Organovo Highlights FXR314 Combination Therapy Potential and Plan

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory ...

3 months ago - GlobeNewsWire

Organovo to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fi...

6 months ago - GlobeNewsWire

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstr...

6 months ago - GlobeNewsWire

Organovo Announces FXR Program

Lead Molecule Poised for Phase 2 in IBD Lead Molecule Poised for Phase 2 in IBD

1 year ago - GlobeNewsWire

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using n...

1 year ago - GlobeNewsWire

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key ...

1 year ago - GlobeNewsWire

Organovo Announces Postponement of Annual Meeting of Stockholders

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key ...

1 year ago - GlobeNewsWire

Organovo Achieves 3D Tissue Model for Crohn's Disease

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel tech...

1 year ago - GlobeNewsWire

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BI...

2 years ago - GlobeNewsWire

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Org...

2 years ago - GlobeNewsWire

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo”), today announced that it has granted a stock option to purchase 50,000 shares of common stock to one ne...

2 years ago - GlobeNewsWire

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting...

2 years ago - GlobeNewsWire

Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that two of its patents have withstood a patent challenge, and the company provided guidance on how...

2 years ago - GlobeNewsWire

Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today released its first detailed response to the lawsuit Cellink (NASDAQ Stockholm: BICO) filed against it in Dela...

2 years ago - GlobeNewsWire

Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today provided a business overview and progress update, and announced it is on track to establish its first models ...

2 years ago - GlobeNewsWire

Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

SOLANA BEACH, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that the Company's annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. ...

2 years ago - GlobeNewsWire

Catherine Wood's ARK Investment Slashes Organovo Holding

Catherine Wood ( Trades , Portfolio)'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceu...

Other symbols: SYRS
3 years ago - GuruFocus

Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)

SOLANA BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences...

3 years ago - GlobeNewsWire

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (“Organovo” or the “Company”) (Nasdaq: ONVO) announced today that it has regained compliance with the minimum bid price requirem...

3 years ago - GlobeNewsWire

Organovo Announces One-for-Twenty Reverse Stock Split

SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (the “Company”) (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of incorporatio...

3 years ago - GlobeNewsWire

Organovo Acknowledges Receipt of Proposal

Reiterates Commitment to Strategic Review Process Reiterates Commitment to Strategic Review Process

4 years ago - GlobeNewsWire